Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed european infants

Pediatric Infectious Disease Journal

Volumn 31, Issue 5, 2012, Pages 509-513

  Vesikari, Timo ^a   Prymula, Roman ^b   Schuster, Volker ^c   Tejedor, Juan C ^d   Cohen, Robert ^e   Bouckenooghe, Alain ^f   Damaso, Silvia ^g   Han, Htay Htay ^g  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d HOSPITAL DE MÓSTOLES   (Spain)

^e Medical Facility   (France)

^f SANOFI PASTEUR   (France)

^g GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Breast feeding; Maternal antibodies; Neutralizing antibodies

Indexed keywords

IMMUNOGLOBULIN A; LIVE VACCINE; ROTAVIRUS VACCINE;

ADOLESCENT; ARTICLE; ARTIFICIAL MILK; BREAST MILK; CHILD; CONTROLLED STUDY; EPIDEMIC; GASTROENTERITIS; HUMAN; HUMAN EXPERIMENT; HUMAN ROTAVIRUS; IMMUNOGENICITY; NORMAL HUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; ROTAVIRUS INFECTION; SEROCONVERSION; VACCINATION;

ANTIBODIES, VIRAL; BREAST FEEDING; CHILD, PRESCHOOL; EUROPE; FEMALE; GASTROENTERITIS; HUMANS; IMMUNOGLOBULIN A; INFANT; INFANT FORMULA; MALE; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SEASONS; TREATMENT OUTCOME; VACCINATION;

EID: 84860255813     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182489cac     Document Type: Article

References (34)

1. World Health Organization. Rotavirus vaccines. Wkly Epidemiol Rec. 2007;82:285-296.
2. Bernstein DI, Sack DA, Rothstein E, et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet. 1999;354:287-290.
3. Vesikari T, Karvonen A, Korhonen T, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine. 2004;22:2836-2842.
4. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J. 2004;23:937-943.
5. Ruiz-Palacios GM, Paez-Schael I, Velquez FR, et al.; Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354:11-22.
6. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007;370:1757-1763.
7. Araujo EC, Clemens SA, Oliveira CS, et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. J Pediatr (Rio J). 2007;83:217-224.
8. Linhares AC, Velquez FR, Paez-Schael I, et al.; Human Rotavirus Vaccine Study Group. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet. 2008;371:1181-1189.
9. Phua KB, Lim FS, Lau YL, et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, doubleblind, controlled study. Vaccine. 2009;27:5936-5941.
10. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010;362:289-298.
11. Narang A, Bose A, Pandit AN, et al. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Hum Vaccin. 2009;5:414-419.
12. Zaman K, Sack DA, Yunus M, et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine. 2009;27:1333-1339.
13. Pichichero ME. Effect of breast-feeding on oral rhesus rotavirus vaccine seroconversion: a metaanalysis. J Infect Dis. 1990;162:753-755.
14. World Health Organization. Infant and young child nutrition: global strategy on infant and young child feeding. Geneva, Switzerland: World Health Organization; 2002. [Resolution WHA55/15].
15. Moon SS, Wang Y, Shane AL, et al. Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediatr Infect Dis J. 2010;29: 919-923.
16. Vesikari T, Ruuska T, Bogaerts H, et al. Dose-response study of RIT 4237 oral rotavirus vaccine in breast-fed and formula-fed infants. Pediatr Infect Dis. 1985;4:622-625.
17. Vesikari T, Ruuska T, Delem A, et al. Oral rotavirus vaccination in breastand bottle-fed infants aged 6 to 12 months. Acta Paediatr Scand. 1986;75: 573-578.
18. Ceyhan M, Kanra G, Séeer G, et al. Take of rhesus-human reassortant tetravalent rotavirus vaccine in breast-fed infants. Acta Paediatr. 1993;82:223-227.
19. Rennels MB, Wasserman SS, Glass RI, et al. Comparison of immunogenicity and efficacy of rhesus rotavirus reassortant vaccines in breastfed and nonbreastfed children. US Rotavirus Vaccine Efficacy Group. Pediatrics. 1995;96:1132-1136.
20. Ray PG, Kelkar SD. Prevalence of neutralizing antibodies against different rotavirus serotypes in children with severe rotavirus-induced diarrhea and their mothers. Clin Diagn Lab Immunol. 2004;11:186-194.
21. Vesikari T, Isolauri E, D'Hondt E, et al. Increased "take" rate of oral rotavirus vaccine in infants after milk feeding. Lancet. 1984;2:700.
22. Cadranel S, Zeglache S, Jonckheer T, et al. Factors affecting antibody response of newborns to repeated administrations of the rotavirus vaccine RIT 4237. J Pediatr Gastroenterol Nutr. 1987;6:525-528.
23. Ward RL, Bernstein DI, Shukla R, et al. Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis. 1989;159:79-88.
24. van Doorn LJ, Kleter B, Hoefnagel E, et al. Detection and genotyping of human rotavirus VP4 and VP7 genes by reverse transcriptase PCR and reverse hybridization. J Clin Microbiol. 2009;47:2704-2712.
25. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis. 1990;22:259-267.
26. Clopper CJ, Pearson E. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404-413.
27. Tang ML, Ng HK. Comment on: confidence limits for the ratio of two rates based on likelihood scores: non-iterative method. Stat Med. 2004;23:685-90; author reply 891.
28. Vesikari T, Karvonen A, Prymula R, et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine. 2010;28:5272-5279.
29. Ruuska T. Occurrence of acute diarrhea in atopic and nonatopic infants: the role of prolonged breast-feeding. J Pediatr Gastroenterol Nutr. 1992;14:27-33.
30. Erkkola M, Salmenhaara M, Kronberg-Kippil C, et al. Determinants of breast-feeding in a Finnish birth cohort. Public Health Nutr. 2010;13: 504-513.
31. Rennels MB. Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. J Infect Dis. 1996;174(suppl 1):S107-S111.
32. Goveia MG, DiNubile MJ, Dallas MJ, et al.; REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatr Infect Dis J. 2008;27: 656-658.
33. Clark HF, Borian FE, Bell LM, et al. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis. 1988;158:570-587.
34. Correia JB, Patel MM, Nakagomi O, et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis. 2010;201: 363-369.